SUPERNUS PHARMACEUTICALS, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2025-02-25
- SUPERNUS PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2024-06-30 was 0.00 shares.
- SUPERNUS PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2024-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2023-09-30 was 0.00 shares.
- SUPERNUS PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2023-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2024 was 0.00 shares.
- SUPERNUS PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- SUPERNUS PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2022 was 6.78M shares.
- SUPERNUS PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2021 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|---|---|
| 2024-12-31 | 0.00 shares 10-K · filed 2025-02-25 | |||||
| 2024-06-30 | 0.00 shares 10-Q · filed 2024-08-06 | 0.00 shares 10-Q · filed 2024-08-06 | ||||
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-08 | |||||
| 2023-12-31 | 0.00 shares 10-K · filed 2025-02-25 | |||||
| 2023-09-30 | 0.00 shares 10-Q · filed 2023-11-08 | 0.00 shares 10-Q · filed 2023-11-08 | ||||
| 2023-06-30 | 0.00 shares 10-Q · filed 2024-08-06 | 3.41M shares 10-Q · filed 2024-08-06 | ||||
| 2023-03-31 | 6.78M shares 10-Q · filed 2024-05-08 | |||||
| 2022-12-31 | 6.78M shares 10-K · filed 2025-02-25 | |||||
| 2022-09-30 | 0.00 shares 10-Q · filed 2023-11-08 | 6.78M shares 10-Q · filed 2023-11-08 | ||||
| 2022-06-30 | 6.78M shares 10-Q · filed 2023-08-08 | 6.78M shares 10-Q · filed 2023-08-08 | ||||
| 2022-03-31 | 6.78M shares 10-Q · filed 2023-05-09 | |||||
| 2021-12-31 | 0.00 shares 10-K · filed 2023-03-09 | |||||
| 2021-09-30 | 0.00 shares 10-Q · filed 2022-11-09 | 0.00 shares 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | 0.00 shares 10-Q · filed 2022-08-08 | 0.00 shares 10-Q · filed 2022-08-08 | ||||
| 2021-03-31 | 0.00 shares 10-Q · filed 2022-05-12 | |||||
| 2020-12-31 | 0.00 shares 10-K · filed 2023-03-09 | |||||
| 2019-12-31 | 0.00 shares 10-K · filed 2020-02-28 | |||||
| 2018-12-31 | 0.00 shares 10-K · filed 2020-02-28 | |||||
| 2017-12-31 | 285.26K shares 10-K · filed 2020-02-28 | |||||
| 2017-09-30 | 56.48K shares 10-Q · filed 2018-11-09 | 382.23K shares 10-Q · filed 2018-11-09 | ||||
| 2017-06-30 | 421.71K shares 10-Q · filed 2018-08-09 | 551.24K shares 10-Q · filed 2018-08-09 | ||||
| 2017-03-31 | 683.74K shares 10-Q · filed 2018-05-10 | |||||
| 2016-12-31 | 1.22M shares 10-K · filed 2019-03-01 | |||||
| 2016-09-30 | 1.24M shares 10-Q · filed 2017-11-09 | 1.27M shares 10-Q · filed 2017-11-09 | ||||
| 2016-06-30 | 1.24M shares 10-Q · filed 2017-08-03 | 1.30M shares 10-Q · filed 2017-08-03 | ||||
| 2016-03-31 | 1.38M shares 10-Q · filed 2017-05-09 | |||||
| 2015-12-31 | 2.46M shares 10-K · filed 2018-03-01 | |||||
| 2015-09-30 | 1.96M shares 10-Q/A · filed 2017-01-20 | 3.70M shares 10-Q/A · filed 2017-01-20 | ||||
| 2015-06-30 | 2.42M shares 10-Q/A · filed 2017-01-23 | |||||
| 2014-12-31 | 7.09M shares 10-K · filed 2016-03-09 | |||||
| 2014-09-30 | 6.75M shares 10-Q · filed 2015-11-09 | 7.58M shares 10-Q · filed 2014-11-12 | 7.31M shares 10-Q · filed 2015-11-09 | 8.00M shares 10-Q · filed 2014-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |